DFTX
Definium Therapeutics Inc.

26,087
Loading...
Loading...
News
all
press releases
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Royal Bank Of Canada lifted their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an "outperform" rating in a report on Friday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High - Here's What Happened
Definium Therapeutics (NASDAQ:DFTX) Reaches New 52-Week High - Here's Why...
MarketBeat·2d ago
News Placeholder
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Business Wire·5d ago
News Placeholder
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol DFTX Effective January 15, 2026
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the 'Company' or Definium') is updating its previous announcement that the Companys Common Shares would begin trading on Nasdaq...
Business Wire·12d ago
News Placeholder
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the 'Company' or Definium') unveiled its new brand today, marking a decisive step forward as the company leads psychiatry toward a...
Business Wire·13d ago
<
...
1
>

Latest DFTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.